Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.84 |
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | CA4 | P22748 | 3/20 | 0.63 |
| ▸ | CA7 | P43166 | 3/20 | 0.63 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.63 |
| ▸ | CA3 | P07451 | 2/20 | 0.63 |
| ▸ | CA6 | P23280 | 2/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22148003 | 0.91 | MAOB (1.00) | MAOBMAOAKMT2ACA12CA2 | |
| SCHEMBL3618447 | 0.86 | MAOB (0.62) | MAOBKMT2AMEN1HSP90AA1KDM4E | |
| SCHEMBL28374375 | 0.86 | SLC16A3 (0.81) | MAOBMAOACA12CA2CA4 | |
| SCHEMBL13073986 | 0.84 | MAOB (0.76) | MAOBMAOACA12CA2CA4 | |
| SCHEMBL27701220 | 0.83 | CA12 (0.74) | MAOBMAOAKMT2ACA12CA2 | |
| SCHEMBL93300 | 0.83 | MAOB (0.85) | MAOBMAOACA12CA2CA4 | |
| SCHEMBL2031783 | 0.82 | MAOB (1.00) | MAOBMAOAKMT2ACA12CA2 | |
| SCHEMBL6415713 | 0.82 | MAOB (0.76) | MAOBMAOACA12CA2CA4 | |
| SCHEMBL93418 | 0.80 | MAOB (0.80) | MAOBMAOASLC16A3 | |
| SCHEMBL6417829 | 0.80 | MAOB (1.00) | MAOBMAOACA12CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842822-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842822-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2009-12-03 | — | — | US | disclosed |
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2009-12-03 | — | — | US | disclosed |
| US-7585985-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585985-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080312312-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2008-12-18 | — | — | US | disclosed |
| US-20080312312-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | DURST GREGORY LEE | 2008-12-18 | — | — | US | disclosed |
| US-7442812-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442812-B2 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1626974-B1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | LILLY CO ELI (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070106082-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106082-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20060194871-A1 | Heterocyclic mchr1 antagoists | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| EP-1626974-A2 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1618112-A1 | HETEROCYCLIC MCHR1 ANTAGONISTS | SmithKline Beecham Corporation (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004094400-A2 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004092181-A1 | HETEROCYCLIC MCHR1 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106082-A1 | Substituted benzopyrans as selective estrogen receptor-beta agonists | MCHR1, MCHR2, MC1R | MAOB 344/4885MAOA 415/4885KMT2A 2161/4885 |
| US-20090298925-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | GPER1, ESR2, ESR1 | MAOB 1407/4885MAOA 1543/4885KMT2A 3905/4885 |
| US-20080312312-A1 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | GPER1, ESR2, ESR1 | MAOB 1407/4885MAOA 1543/4885KMT2A 3905/4885 |
| US-20060194871-A1 | Heterocyclic mchr1 antagoists | MCHR1, MCHR2, MC1R | MAOB 238/4885MAOA 200/4885KMT2A 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.